At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 394 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension
In Brief
A Phase 2 clinical trial evaluating Placebo and ALN-AGT01 for Hypertension. Completed, enrolled 394 participants across 75 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCanada, Puerto Rico, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionApr 2023
Study CompletionDec 2024
TodayJul 2026
First PostedJun 23, 2021
Enrollment StartJul 7, 2021
Primary CompletionApr 4, 2023
Study CompletionDec 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.0 years ago
Interventions
Placebodrug
Placebo administered by SC injection
ALN-AGT01drug
ALN-AGT01 administered by SC injection